Talha K, PharmD, BCOP (@talhakhanrx) 's Twitter Profile
Talha K, PharmD, BCOP

@talhakhanrx

Heme/Onc PharmD at Northwestern. STLCOP alumni. PGY1 & PGY2 Onc at Northwestern. Views are my own.

ID: 1383039531222458371

calendar_today16-04-2021 12:48:33

120 Tweet

161 Followers

285 Following

Graham Collins (@graham74gc) 's Twitter Profile Photo

So here are the curves for SWOG S1836 - AAVD v AVD-nivo. 1 y PFS 94% N-AVD vs 86%. Impressive result but 1y PFS is a pretty early endpoint. Very interesting to see if the differences hold. Safety looking v good for AVD-N.

Talha Badar (@talhabadarmd) 's Twitter Profile Photo

QuANTUM-First trial that led to approval of Quizartinib doi.org/10.1016/S0140-… Key differences compared to RATIFY: 1. Patient were older up to 75 y compared to 60 y; more, high-risk, sAML 3. Pts with FLT3 TID only 4. Quizartinib maint. up to 3 y compared 👉 1 y in RATIFY

Muzaffar Qazilbash (@transplant_doc) 's Twitter Profile Photo

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma | NEJM. CARTITUDE-4 #mmsm #bmtsm nejm.org/doi/full/10.10…

Chan Cheah (@chanyooncheah) 's Twitter Profile Photo

A pleasure to share this work from Katharine Lewis et al re: high-dose methotrexate as CNS Prophylaxis in High-Risk B-Cell lymphoma just out in Journal of Clinical Oncology HUGE international effort spanning years: thanks ++ to all collaborators #lymSM #CNSprophylaxis ascopubs.org/doi/10.1200/JC…

Robert Brodsky (@docsdock200) 's Twitter Profile Photo

ASH23 Practice Changing LBAs are out! 1)Perseus trial primary results. (dex,VRd over VRd) #myeloma 2)BMT-CTN1507: HaploBMT in adults with severe SCD. Curative therapy for SCD. Widely available in US. Cure rates ~90%. 10x less expensive than gene therapy/editing. #sicklecell

Irum Khan (@irumkhan_hem) 's Twitter Profile Photo

A prospective approach linking individual level pt reported SDOH data to early adverse AML outcomes. Proud of Eshana Shah for an excellent oral abstract and the dedicated efforts of leukemia teams, trainees and patients University of Illinois Cancer Center and Lurie Cancer Center

A prospective approach linking individual level pt reported SDOH data to early adverse AML outcomes. Proud of <a href="/EshanaShahMD/">Eshana Shah</a>  for an excellent oral abstract and the dedicated efforts of leukemia teams, trainees and patients <a href="/UICancerCenter/">University of Illinois Cancer Center</a> and <a href="/LurieCancer/">Lurie Cancer Center</a>
Talha K, PharmD, BCOP (@talhakhanrx) 's Twitter Profile Photo

Cilta-cel box warning updated to include MDS/AML in 10% (10/97) of patients following treatment in the CARTITUDE-1 study. investors.legendbiotech.com/node/8351/html

Jessica Altman, MD (@jaltmanmd) 's Twitter Profile Photo

Today was one of those days that our #PharmDs went above & beyond to care for our #AML pts. Actually, that happens every day….Thank you Talha K, PharmD, BCOP Magda Dankowska and team for today and all the days I forget to share my 💜 and appreciation. Lurie Cancer Center Northwestern Medicine

AmericanJournalofHematology (@ajhematology) 's Twitter Profile Photo

Ven Less is More: Ven 14 days non-inferior to 28 days in newly-diagnosed acute myeloid leukemia. onlinelibrary.wiley.com/doi/epdf/10.10…

Ven Less is More: Ven 14 days non-inferior to 28 days in newly-diagnosed acute myeloid leukemia.

onlinelibrary.wiley.com/doi/epdf/10.10…
Talha Badar (@talhabadarmd) 's Twitter Profile Photo

Weekend review 1/11 Outcome of MDS progressing on hypomethylating agent has dismal OS in the range of 6-9 months; worse with #TP53m No approved therapy for this poor prognostic disease. doi.org/10.1038/s41408… 👇🏽 🧵 on prospective and retrospective studies.

Weekend review 

1/11 Outcome of MDS progressing on hypomethylating agent has dismal OS in the range of 6-9 months; worse with #TP53m 

No approved therapy for this poor prognostic disease.

doi.org/10.1038/s41408…

👇🏽 🧵 on prospective and retrospective studies.
Talha K, PharmD, BCOP (@talhakhanrx) 's Twitter Profile Photo

Today marks my last time rounding on the leukemia service. My heartfelt thanks to everyone at NM for all the love & encouragement over the years. You will always have a piece of my heart. Jessica Altman, MD Yasmin Abaza Irum Khan Northwestern Medicine Lurie Cancer Center

Today marks my last time rounding on the leukemia service. My heartfelt thanks to everyone at NM for all the love &amp; encouragement over the years. You will always have a piece of my heart. <a href="/jaltmanmd/">Jessica Altman, MD</a> <a href="/yasminabaza1/">Yasmin Abaza</a> <a href="/Irumkhan_hem/">Irum Khan</a> <a href="/NorthwesternMed/">Northwestern Medicine</a> <a href="/LurieCancer/">Lurie Cancer Center</a>